William Garvey
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1114947769
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 32.6% of the total. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $1163.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$137K
- Novo Nordisk AS$118K
- Boehringer Ingelheim$53K
- Lilly USA, LLC$22K
- Regeneron$21K
- Eli Lilly$15K
- plus $55K from 20 others
Across 3,340 payments — averaging $1018.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2.9M
- Eli Lilly$316K
- F. Hoffmann-la Roche AG$52K
- Genentech, Inc.$39K
- Sanofi US Services Inc.$29K
- Boehringer Ingelheim International GmbH$27K
- plus $21K from 6 others
What the payments were for
- Consulting fees$244,54058%
- Speaking & faculty fees$35,2888%
- Travel & lodging$126,48330%
- Food & beverage$14,5683%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 96 | $137,367 |
| Novo Nordisk AS | 71 | $117,500 |
| Boehringer Ingelheim | 60 | $52,678 |
| Lilly USA, LLC | 5 | $22,097 |
| Regeneron | 35 | $20,851 |
| Eli Lilly | 13 | $15,496 |
| Amgen | 10 | $6,916 |
| Zealand Pharma A/s | 7 | $6,510 |
| Merck | 11 | $6,405 |
| Neurocrine Biosciences, Inc. | 8 | $5,895 |
| AbbVie | 7 | $5,595 |
| Inogen, Inc. | 2 | $5,144 |
| Pfizer | 4 | $4,754 |
| Corcept Therapeutics | 8 | $4,466 |
| Genentech USA, Inc. | 6 | $3,312 |
| Madrigal Pharmaceuticals | 6 | $2,590 |
| F. Hoffmann-la Roche AG | 1 | $2,000 |
| Genentech, Inc. | 1 | $425 |
| Janssen Scientific Affairs, LLC | 3 | $389 |
| Sanofi-aventis U.S. LLC | 1 | $126 |
| Abbott | 1 | $124 |
| Bayer | 1 | $115 |
| Valeritas, Inc. | 1 | $106 |
| Johnson & Johnson | 1 | $75 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$421,015 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.